Rubius Therapeutics, Inc. (RUBY) |
|
0.01543 0 (0.85%)
|
03-27 15:59 |
|
Open: |
0.0153 |
Pre. Close: |
0.0153 |
|
High:
|
0.0155 |
Low:
|
0.015 |
|
Volume:
|
125,746 |
Market Cap:
|
1(M) |
|
|
|
Technical analysis |
as of: 2023-03-27 4:22:45 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 0.14 One year: 0.21 |
| Support: |
Support1: 0.01 Support2: 0.01 |
| Resistance: |
Resistance1: 0.12 Resistance2: 0.18 |
| Pivot: |
0.03  |
| Moving Average: |
MA(5): 0.01 MA(20): 0.05
MA(100): 0.18 MA(250): 0.72 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 2.6 %D(3): 1.9 |
| RSI: |
RSI(14): 23.4 |
| 52-week: |
High: 6.17 Low: 0.01 |
| Average Vol(K): |
3-Month: 4,414 (K) 10-Days: 2,420 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ RUBY ] has closed above bottom band by 29.1%. Bollinger Bands are 46.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.02 - 0.02 |
0.02 - 0.02 |
|
Low:
|
0.01 - 0.01 |
0.01 - 0.02 |
|
Close:
|
0.02 - 0.02 |
0.02 - 0.02 |
|
Company Description |
|
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was incorporated in 2013 and is headquartered in Cambridge, Massachusetts. |
Headline News |
Mon, 06 Mar 2023
U.S. shares mixed at close of trade; Dow Jones Industrial Average ... - Investing.com India
Mon, 06 Mar 2023
Why Hertz Global Shares Are Trading Higher By Around 5%; Here ... - Investing.com UK
Mon, 06 Mar 2023
U.S. stocks mixed at close of trade; Dow Jones Industrial Average up ... - Investing.com
Fri, 03 Mar 2023
ObsEva SA (NASDAQ:OBSV) surges 86.6% after announcing ... - Best Stocks
Fri, 03 Mar 2023
RUBIUS THERAPEUTICS, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Change in Directors or Principal Officers (form 8-K) - Marketscreener.com
Wed, 22 Feb 2023
Rubius Therapeutics Outlines Dissolution Plan, After Unsuccessful Attempt On Alternatives - Yahoo Finance
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
90 (M) |
| Shares Float |
46 (M) |
|
% Held by Insiders
|
5.5 (%) |
|
% Held by Institutions
|
76 (%) |
|
Shares Short
|
1,870 (K) |
|
Shares Short P.Month
|
2,040 (K) |
Stock Financials |
|
EPS
|
-2.08 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
1.75 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-42.1 |
|
Return on Equity (ttm)
|
-164.6 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-1.88 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-155 (M) |
|
Levered Free Cash Flow
|
-86 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-0.01 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
